In conclusion this study suggests a possible role for increased expression of Tbet in CD4+ T cells as a biomarker for early conversion from CIS to CDMS and warrants further exploration in larger, longitudinal cohorts. This evidence concerns the gene TBX21 and in situ carcinoma.